Home>Topics>Stocks>Arena Pharmaceuticals

Arena Pharmaceuticals ARNA

  1. All
  2. Commentary
  3. Headlines
    1. Assessing Arena Pharmaceutical Belviq Sales And The Impact Of TV Ads

      Headlines

      Wed, 22 Oct 2014

      Assessing Arena Pharmaceutical Belviq Sales And The Impact Of TV Ads

    2. Arena Investors Need To Watch Contrave Launch Closely

      Headlines

      Wed, 22 Oct 2014

      Arena Investors Need To Watch Contrave Launch Closely

    3. Orexigen Launches Contrave - Watch For Traction

      Headlines

      Mon, 20 Oct 2014

      By Spencer Osborne : Orexigen (NASDAQ: OREX ) announced today that the anti-obesity drug Contrave is now available for prescriptions in the United States. Orexigen's marketing partner Takeda has set up several ways that consumers can save money on their weight-loss medication as well as monitor ...

    4. Are People Too Concerned About Orexigen's Contrave Label?

      Headlines

      Sun, 19 Oct 2014

      anti-obesity drug to be approved by the FDA in over 10 years. This is following the approval of Belviq ( Arena Pharmaceuticals (NASDAQ: ARNA )) and Qsymia (Vivus (NASDAQ: VVUS )) back in 2012. Following its approval, OREX stock has tanked

    5. Belviq Sales Dip: What To Watch For Ahead

      Headlines

      Fri, 17 Oct 2014

      By Spencer Osborne : Sales of the Arena Pharmaceuticals (NASDAQ: ARNA ) anti-obesity pill Belviq seem to be seeing some impacts of seasonality with ups and downs as the Fall weeks progress. This

    6. What To Watch For As Orexigen's Launch Approaches

      Headlines

      Thu, 16 Oct 2014

      toward healthcare there is no denying that Wall Street will be there as well. When launched, Orexigen will join Arena (NASDAQ: ARNA ) and Vivus (NASDAQ: VVUS ) as one of three companies with FDA approved anti-obesity drugs on the market. Other players

    7. Pfizer Setback Could Help Arena

      Headlines

      Wed, 15 Oct 2014

      impressive sales numbers, though sales in the most recent years are not the same as they were at their peak. The news surrounding Chantix surfaces at a time when Arena Pharmaceuticals (NASDAQ: ARNA ) and its marketing partner Complete Story »

    8. Belviq Sales Rise Almost 5% Week Over Week

      Headlines

      Fri, 10 Oct 2014

      By Spencer Osborne : Sales of Belviq, the anti-obesity drug from Arena Pharmaceuticals (NASDAQ: ARNA ) were up this week and now pacing slightly ahead of the "guidance" pace I outlined many months ago. When you look at my weekly

    9. After Hour Gainers / Losers

      Headlines

      Tue, 7 Oct 2014

      Top gainers, as of 5:15 p.m.: UNIS +15.7% . RBCN +4.4% . HERO +4.2% . FBR +2.8% . OTCQB:GSAT +2.5%. Top losers, as of 5:15 p.m.: TILE -23.0% . GPRO -2.7% . SAVE -2.4% . ARNA -2.3% . BKW -2.3% . Post your comment!

    10. Orexigen On A Tear - In The Wrong Direction

      Headlines

      Tue, 7 Oct 2014

      that all of the hype and potential of the market size fizzled when Vivus (NASDAQ: VVUS ) launched Qsymia and Arena (NASDAQ: ARNA ) launched Belviq. It was not long after the launch of these drugs that the market came to realize that the anti-obesity sector

    « Prev12345Next »
    Content Partners